期刊
CURRENT OPINION IN IMMUNOLOGY
卷 24, 期 2, 页码 207-212出版社
CURRENT BIOLOGY LTD
DOI: 10.1016/j.coi.2011.12.009
关键词
-
类别
资金
- NIH [R01 CA142779, R01 CA127153, 1P50CA58236-15]
- Melanoma Research Alliance
- Laverna Hahn Charitable Trust
- Barney Family Foundation
- Patrick C. Walsh Fund
- OneInSix Foundation
- Prostate Cancer Foundation
- Bristol-Myers Squibb
Genetic alterations and epigenetic dysregulation in cancer cells create a vast array of neoepitooes potentially recognizable by the immune system. Immune checkpoint blockade has the capacity to enhance and sustain endogenous immunity against non-mutated tumor-associated antigens as well as uniquely mutant antigens, establishing durable tumor control. Recent evidence from preclinical models highlights the pivotal role of the Programmed Death-1 (PD-1) T cell co-receptor and its ligands, B7-H1/PD-L1 and B7-DC/PD-L2, in maintaining an immunosuppressive tumor microenvironment. Encouraging early clinical results using blocking agents against components of the PD-1 pathway have validated its importance as a target for cancer immunotherapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据